Project Grant R01CA316222
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Cancer Institute awarded Emory University $402,401 on May 6, 2026, for development of an F-18 imaging agent to measure glioma IDH1 mutant expression under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The funded work develops a positron emission tomography tracer to non-invasively measure mutated cytosolic NADP+-dependent isocitrate dehydrogenase (IDH1) activity in low-grade glioma and secondary glioblastoma multiforme. IDH1 mutations occur in more than 70...
- The National Cancer Institute awarded Vanderbilt University Medical Center $543,816 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to validate the molecular origin of APT-weighted imaging in tumors. The recipient will develop and apply Chemical Exchange Saturation Transfer (CEST) editing techniques to separate amide proton transfer (APT) and nuclear Overhauser effect (NOE) signals from amine CEST, clarifying the true source of APT-weighted...
- The National Cancer Institute awarded Yale University $607,690 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an MR-based platform for simultaneous intracellular pH (PHI) and extracellular pH (PHE) imaging in glioblastoma multiforme (GBM). The research aims to distinguish glycolytic and oxidative tumor phenotypes by measuring transmembrane pH gradients, which are larger in tumors than normal tissue and vary between metabolic phenotypes....
- The National Cancer Institute awarded the University of Virginia $404,349 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on April 1, 2026, to develop and validate quantitative magnetic resonance imaging methods for measuring macromolecular delivery to brain tumors following focused ultrasound and microbubble treatment. The research addresses the blood-tumor barrier, which limits therapeutic drug delivery to brain metastases and contributes to higher patient mortality...
- The National Cancer Institute awarded the University of California, Los Angeles $640,597 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize and therapeutically target pH-regulatory mechanisms in glioblastoma using amine chemical exchange saturation transfer echo-planar imaging (CEST-EPI) and novel treatment approaches. The project develops CEST-EPI, a pH-sensitive magnetic resonance imaging technique that enables high-resolution visualization...
- The National Cancer Institute awarded Vanderbilt University Medical Center $701,332 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate MRI cytometry as a noninvasive imaging biomarker for characterizing renal masses and distinguishing benign from malignant tumors. The project applies advanced diffusion MRI technique with multicompartment biophysical modeling to generate voxelwise maps of cell size and cellularity at...
- The National Cancer Institute awarded The Medical College of Wisconsin, Inc. $602,121 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, to develop and validate advanced radio-pathomic mapping techniques that predict pathological tumor characteristics in glioblastoma using standard clinical MRI. The research addresses non-enhancing tumor regions that extend beyond visible MRI enhancement and harbor resistant cells serving as recurrence reservoirs, regions...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $431,970 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to refine and validate an MRI-based imaging technique for detecting tumor microenvironment of metastasis (TMEM) doorways in breast cancer. The award funds development of TMEM doorway activity-MRI (TDAM), a dynamic contrast-enhanced MRI method designed to measure vascular opening events...
- The National Cancer Institute awarded Emory University $602,170 on June 2, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop biomimetic migrating nanoparticles targeting tumor stroma and neural invasion in pancreatic cancer. The recipient is developing a tumor cell mimetic hyaluronic acid nanoparticle drug delivery platform conjugated with a recombinant atfmmp14 ligand containing the amino-terminal fragment of urokinase plasminogen activator and an MMP14...
- The National Cancer Institute awarded Wayne State University $513,901 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct translational imaging research on the tryptophan-kynurenine pathway in human gliomas. The award funds development and clinical translation of a novel positron-emission tomography radiotracer ([18F]fluoroethyl-L-tryptophan, [18F]FETRP) to improve detection and evaluation of glioblastoma. The project will employ multi-modal...